<DOC>
	<DOCNO>NCT00497614</DOCNO>
	<brief_summary>Biologics routinely use treatment rheumatoid arthritis ( RA ) . Adalimumab human monoclonal antibody inhibit Tumor Necrosis Factor alpha ( TNF-alpha ) . Identification RA patient respond biologics challenge goal avoid unnecessarily , costly potentially harmful treatment . The aim study address 18 F FDG valuable biomarker assessment clinical response RA TNF-alpha block agent . Eight patient fulfil ACR ( American College Rheumatology ) criterion enrol . Patient receive adalimumab accord current guideline i.e . 40mg /14 day sub cutaneously . The decision stand high activity disease define DAS 28 ( Disease Activity Score ) 5.1 . Positron emission tomography perform , 2 12 week begin treatment . The response adalimumab assess SUV ( standard Unit value ) measure inflammatory joint hand , wrist , ankle , foot knee compare measurement clinical ( total swell tender joint count ) echographic ( synovium thickness power doppler ) chemical biomarkers ( erythrocyte sedimentation rate , C reactive protein ) .</brief_summary>
	<brief_title>Positron Emission Tomography Rheumatoid Arthritis With Adalimumab ( PETRA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients active Rheumatoid arthritis PR définie selon les critères ACR ( 1987 ) ( annexe 7 ) [ 18 ] , Activité importante de la maladie ( DAS 28 &gt; 5,1 ) ( annexe 5 ) [ 7 ] , Indication d'un traitement par adalimumab ( en accord avec l ' A.M.M . ) , Homme ou femme dont l'âge est supérieur ou égal à 18 an , Acceptant de participer à l'étude et ayant donné son consentement éclairé , Affiliés ou bénéficiaire d'un régime de sécurité sociale .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Positron emission tomodensitometry</keyword>
	<keyword>Tumor necrosis factor alpha inhibitor</keyword>
</DOC>